Editas Medicine, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
EDIT Nasdaq 2834 www.editasmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Editas Medicine, Inc.

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report? - Jun 4th, 2026 9:30 am
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - May 31st, 2026 10:31 am
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference - May 28th, 2026 2:01 pm
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering - May 26th, 2026 7:05 am
Editas Medicine Announces Proposed Public Offering - May 26th, 2026 4:15 am
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress - May 26th, 2026 4:01 am
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - May 21st, 2026 11:30 am
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting - May 14th, 2026 4:01 am
Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates - May 11th, 2026 7:35 am
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus - May 6th, 2026 9:57 am
Company News for May 6, 2026 - May 6th, 2026 7:39 am
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2026 6:25 am
Editas Medicine Announces First Quarter 2026 Results and Business Updates - May 5th, 2026 5:00 am
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - Apr 27th, 2026 2:31 pm
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? - Apr 15th, 2026 9:30 am
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Apr 13th, 2026 7:00 am
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue? - Apr 8th, 2026 9:30 am
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Apr 7th, 2026 7:00 am
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - Mar 27th, 2026 5:00 am
Is Editas Medicine Going to $0? - Mar 17th, 2026 3:50 pm